Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVBPNASDAQ:CGONNYSE:JNJNASDAQ:UPBNASDAQ:UPB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVBPArriVent BioPharma$21.26+1.7%$20.00$15.47▼$36.37$723.18M1.66171,767 shs183,727 shsCGONCG Oncology$26.94$23.58$14.80▼$46.99$2.05B1.24783,695 shs1.66 million shsJNJJohnson & Johnson$156.32+0.3%$159.36$140.68▼$169.99$376.12B0.497.92 million shs9.59 million shsUPBUpstream Bio$9.26+3.1%$7.90$5.14▼$29.46$497.16MN/A323,473 shs189,688 shsUPBUpstream Bio$9.26+3.1%$7.90$5.14▼$29.46$497.16MN/A323,473 shs189,688 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVBPArriVent BioPharma-0.10%+3.06%+10.29%-27.98%+27.91%CGONCG Oncology-3.68%+31.54%+1.97%-11.06%-37.81%JNJJohnson & Johnson+0.35%-1.13%-4.72%+3.06%+6.17%UPBUpstream Bio+2.28%-11.53%+30.71%-12.39%+897,999,900.00%UPBUpstream Bio+2.28%-11.53%+30.71%-12.39%+897,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVBPArriVent BioPharma1.0033 of 5 stars3.60.00.00.01.80.00.0CGONCG Oncology2.0987 of 5 stars4.50.00.00.03.00.80.0JNJJohnson & Johnson4.2943 of 5 stars2.33.04.23.92.72.50.6UPBUpstream BioN/AN/AN/AN/AN/AN/AN/AN/AUPBUpstream BioN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVBPArriVent BioPharma 3.17Buy$39.0083.44% UpsideCGONCG Oncology 3.00Buy$59.56121.07% UpsideJNJJohnson & Johnson 2.63Moderate Buy$171.829.92% UpsideUPBUpstream Bio 3.00Buy$56.50510.15% UpsideUPBUpstream Bio 3.00Buy$56.50510.15% UpsideCurrent Analyst Ratings BreakdownLatest UPB, CGON, AVBP, JNJ, and UPB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/29/2025CGONCG OncologyRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$66.00 ➝ $68.004/28/2025CGONCG OncologyCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$75.00 ➝ $75.004/28/2025CGONCG OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.00 ➝ $75.004/24/2025JNJJohnson & JohnsonBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/17/2025JNJJohnson & JohnsonBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$166.00 ➝ $165.004/16/2025JNJJohnson & JohnsonSanford C. BernsteinSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform4/16/2025CGONCG OncologyScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Perform$23.004/16/2025JNJJohnson & JohnsonRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$181.00 ➝ $181.004/16/2025JNJJohnson & JohnsonMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$164.00 ➝ $169.004/14/2025JNJJohnson & JohnsonRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$165.00 ➝ $162.004/10/2025JNJJohnson & JohnsonBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$171.00 ➝ $159.00(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVBPArriVent BioPharmaN/AN/AN/AN/A($4.79) per shareN/ACGONCG Oncology$1.14M1,802.71N/AN/A($1.94) per share-13.89JNJJohnson & Johnson$89.33B4.21$12.84 per share12.17$29.69 per share5.27UPBUpstream Bio$2.37M209.77N/AN/AN/A∞UPBUpstream Bio$2.37M209.77N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVBPArriVent BioPharma-$69.33M-$2.57N/AN/AN/AN/A-43.89%-29.67%5/14/2025 (Estimated)CGONCG Oncology-$48.61M-$1.42N/AN/AN/A-10,642.98%-18.97%-15.36%5/8/2025 (Estimated)JNJJohnson & Johnson$14.07B$8.9923.5114.122.5618.20%34.24%13.63%7/16/2025 (Estimated)UPBUpstream BioN/AN/A0.00N/AN/AN/AN/AN/A6/11/2025 (Estimated)UPBUpstream BioN/AN/A0.00N/AN/AN/AN/AN/A6/11/2025 (Estimated)Latest UPB, CGON, AVBP, JNJ, and UPB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025AVBPArriVent BioPharma-$0.66N/AN/AN/AN/AN/A5/8/2025Q1 2025CGONCG Oncology-$0.36N/AN/AN/AN/AN/A4/15/2025Q1 2025JNJJohnson & Johnson$2.59$2.77+$0.18$4.54$21.65 billion$21.89 billion3/25/2025Q4 2024CGONCG Oncology-$0.37-$0.48-$0.11-$0.48$0.11 million$0.46 million3/3/2025Q4 2024AVBPArriVent BioPharma-$0.78-$0.60+$0.18-$0.61N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVBPArriVent BioPharmaN/AN/AN/AN/AN/ACGONCG OncologyN/AN/AN/AN/AN/AJNJJohnson & Johnson$5.203.33%+5.43%57.84%64 YearsUPBUpstream BioN/AN/AN/AN/AN/AUPBUpstream BioN/AN/AN/AN/AN/ALatest UPB, CGON, AVBP, JNJ, and UPB DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/15/2025JNJJohnson & Johnsonquarterly$1.303.37%5/27/20255/27/20256/10/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVBPArriVent BioPharmaN/A19.2819.28CGONCG OncologyN/A35.3235.32JNJJohnson & Johnson0.431.110.86UPBUpstream BioN/AN/AN/AUPBUpstream BioN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVBPArriVent BioPharma9.48%CGONCG Oncology26.56%JNJJohnson & Johnson69.55%UPBUpstream BioN/AUPBUpstream BioN/AInsider OwnershipCompanyInsider OwnershipAVBPArriVent BioPharmaN/ACGONCG OncologyN/AJNJJohnson & Johnson0.16%UPBUpstream BioN/AUPBUpstream BioN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVBPArriVent BioPharma4034.02 millionN/AN/ACGONCG Oncology6176.22 millionN/AOptionableJNJJohnson & Johnson152,7002.41 billion2.40 billionOptionableUPBUpstream Bio3853.69 millionN/AN/AUPBUpstream Bio3853.69 millionN/AN/AUPB, CGON, AVBP, JNJ, and UPB HeadlinesRecent News About These CompaniesNantahala Capital Management LLC Acquires Shares of 600,000 Upstream Bio, Inc. (NASDAQ:UPB)April 30 at 8:15 AM | marketbeat.comJPMorgan Chase & Co. Acquires Shares of 47,792 Upstream Bio, Inc. (NASDAQ:UPB)April 30 at 3:03 AM | marketbeat.comLynx1 Capital Management LP Makes New Investment in Upstream Bio, Inc. (NASDAQ:UPB)April 29 at 7:00 AM | marketbeat.comDecheng Capital LLC Buys Shares of 3,285,293 Upstream Bio, Inc. (NASDAQ:UPB)April 28 at 7:18 AM | marketbeat.comGeode Capital Management LLC Purchases New Position in Upstream Bio, Inc. (NASDAQ:UPB)April 28 at 3:14 AM | marketbeat.comMarshall Wace LLP Makes New $4.78 Million Investment in Upstream Bio, Inc. (NASDAQ:UPB)April 27 at 4:13 AM | marketbeat.comUpstream Bio (NASDAQ:UPB) Trading 7.2% Higher - Here's What HappenedApril 23, 2025 | marketbeat.comBain Capital Life Sciences Investors LLC Acquires New Holdings in Upstream Bio, Inc. (NASDAQ:UPB)April 23, 2025 | marketbeat.comUpstream Bio: Verekitug, A Longer-Acting Dupixent? - Key Data Is ImminentApril 17, 2025 | seekingalpha.comFmr LLC Purchases New Position in Upstream Bio, Inc. (NASDAQ:UPB)April 16, 2025 | marketbeat.comUpstream Bio Stock Price, Quotes and Forecasts | NASDAQ:UPB | BenzingaApril 11, 2025 | benzinga.comUpstream Bio (NASDAQ:UPB) Is In A Good Position To Deliver On Growth PlansApril 11, 2025 | finance.yahoo.comAlliancebernstein L.P. Invests $18.27 Million in Upstream Bio, Inc. (NASDAQ:UPB)April 9, 2025 | marketbeat.comWellington Management Group LLP Makes New $25.63 Million Investment in Upstream Bio, Inc. (NASDAQ:UPB)April 9, 2025 | marketbeat.comNorges Bank Invests $16.44 Million in Upstream Bio, Inc. (NASDAQ:UPB)April 9, 2025 | marketbeat.comUpstream Bio, Inc.'s Lock-Up Period Will Expire on April 9th (NASDAQ:UPB)April 3, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Invests $2.23 Million in Upstream Bio, Inc. (NASDAQ:UPB)March 30, 2025 | marketbeat.comUpstream Bio, Inc.: Promising Outlook with Strategic Positioning and Strong Trial ExecutionMarch 19, 2025 | tipranks.comUpstream Bio’s Financial Results and Strategic ProgressMarch 13, 2025 | tipranks.comPromising Developments and Strong Financial Position Drive Buy Rating for Upstream Bio, Inc.March 12, 2025 | tipranks.comUpstream Bio, Inc. Completes Enrollment in Phase 2 Trial of Verekitug for Chronic Rhinosinusitis and Raises $293 Million in IPOMarch 12, 2025 | quiverquant.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Texas Instruments: Earnings Beat, Upbeat Guidance Fuel RecoveryBy Jeffrey Neal Johnson | April 27, 2025View Texas Instruments: Earnings Beat, Upbeat Guidance Fuel Recovery3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.By Leo Miller | April 28, 2025View 3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.Johnson & Johnson Earnings Were More Good Than Bad—Time to Buy? By Chris Markoch | April 16, 2025View Johnson & Johnson Earnings Were More Good Than Bad—Time to Buy? UPB, CGON, AVBP, JNJ, and UPB Company DescriptionsArriVent BioPharma NASDAQ:AVBP$21.26 +0.36 (+1.72%) As of 04:00 PM EasternArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.CG Oncology NASDAQ:CGON$26.94 0.00 (0.00%) As of 04:00 PM EasternCG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.Johnson & Johnson NYSE:JNJ$156.32 +0.41 (+0.26%) As of 03:59 PM EasternJohnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.Upstream Bio NASDAQ:UPB$9.26 +0.28 (+3.12%) As of 04:00 PM EasternUpstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.Upstream Bio NASDAQ:UPB$9.26 +0.28 (+3.12%) As of 04:00 PM EasternUpstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Soars on Novo Nordisk Collaboration 3 Dividend Kings Outshining the Market in 2025 Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged Amazon's Earnings Will Make or Break the Stock's Comeback Why D-Wave's Project With Davidson Is a Game-Changer For Quantum NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone Joby Aviation Shares Eye Breakout After Transition Flight Win Altria’s Resilient Strategy Keeps It a Top Dividend Play in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
